



BOX PATENT

Attorney Docket No. 23758

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:) Group Art Unit: 1614
)
Gregory S. HAMILTON)
)
Serial No. 09/741,437)
)
Filed: December 21, 2000)

RECEIVED

JUL 10 2001

TECH CENTER 1600/2900

For: **HYDANTOIN DERIVATIVE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS,
AND METHODS OF USING SAME**

TRANSMITTAL LETTER

Commissioner for Patents
Washington, D.C. 20231

Sir:

Submitted herewith for filing in the U.S. Patent and
Trademark Office is the following:

- (1) Transmittal Letter;
- (2) First Supplemental Information Disclosure Statement;
- (3) PTO-Form 1449; and
- (4) Copies of Thirty-One (31) references cited.

Please charge any required fee, or credit any overpayment,
in connection with this matter to deposit Account No. 14-0112.

Respectfully submitted,

NATH & ASSOCIATES PLLC

Date: July 5, 2001
NATH & ASSOCIATES PLLC
1030 Fifteenth Street, N.W.
Sixth Floor
Washington, D.C. 20005
Tel: (202) 775-8383
FAX: (202) 775-8396
GMN:TLJ:JBG:\lsids.tl.wpd

Leo J. Annan
Gary M. Nath
Reg. No. 26,965
Todd L. Juneau
Reg. No. 40,669
Customer No. 20529



BOX PATENT
Attorney Docket No. 23758

#3
M.J.
7/20/01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

In re Application of:) Group Art Unit: 1614
)
Gregory S. HAMILTON)
)
Serial No. 09/741,437)
)
Filed: December 21, 2000)

JUL 10 2001

TECH CENTER 1600/2900

For: **HYDANTOIN DERIVATIVE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS,
AND METHODS OF USING SAME**

FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

Pursuant to Applicant's duty of disclosure under 37 C.F.R. §§1.56 and 1.97-1.99, the documents listed on the attached Form PTO-1449 are being brought to the attention of the Examiner in charge of the above-identified application. No fee is required for this submission because it is submitted prior to the mailing of a First Office Action on the merits.

Copies of the documents are attached herewith with a completed Form PTO-1449. The Examiner is respectfully requested to cite the documents listed on the attached Form PTO-1449 in the next Office Action. In so doing, the Examiner is respectfully requested to initial in the space adjacent to the listing of each document on the Form PTO-1449, and return a copy of the initialed Form PTO-1449 with the next communication to Applicants, to confirm that these documents have been considered by the Examiner


and made of record in this application.

If the Examiner has any questions or wishes to discuss this application, kindly telephone the undersigned at the below-listed number.

Respectfully submitted,

NATH & ASSOCIATES PLLC

Date: July 5, 2001
NATH & ASSOCIATES PLLC
1030 Fifteenth Street, N.W.
Sixth Floor
Washington, D.C. 20005
Tel: (202) 775-8383
FAX: (202) 775-8396
GMN:TLJ:JBG:\1sIDS.wpd


Gary M. Nath
Reg. No. 26,965
Todd L. Juneau
Reg. No. 40,669
Customer No. 20529



#2

BOX PATENT

Attorney Docket No. 23758

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:) Group Art Unit: 1614
Gregory S. HAMILTON)
Serial No. 09/741,437)
Filed: December 21, 2000)

For: **HYDANTOIN DERIVATIVE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS,
AND METHODS OF USING SAME**

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

Pursuant to Applicant's duty of disclosure under 37 C.F.R. §§1.56 and 1.97-1.99, the documents listed on the attached Form PTO-1449 are being brought to the attention of the Examiner in charge of the above-identified application. No fee is required for this submission because it is submitted prior to the mailing of a First Office Action on the merits.

Copies of the documents are attached herewith with a completed Form PTO-1449. The Examiner is respectfully requested to cite the documents listed on the attached Form PTO-1449 in the next Office Action. In so doing, the Examiner is respectfully requested to initial in the space adjacent to the listing of each document on the Form PTO-1449, and return a copy of the initialed Form PTO-1449 with the next communication to Applicants, to confirm that these documents have been considered by the Examiner

and made of record in this application.

If the Examiner has any questions or wishes to discuss this application, kindly telephone the undersigned at the below-listed number.

Respectfully submitted,

NATH & ASSOCIATES PLLC

Date: July 5, 2001

NATH & ASSOCIATES PLLC

1030 Fifteenth Street, N.W.
Sixth Floor

Washington, D.C. 20005

Tel: (202) 775-8383

FAX: (202) 775-8396

GMN:TLJ:JBG:\IDS.wpd



Gary M. Nath

Reg. No. 26,965

Todd L. Juneau

Reg. No. 40,669

Customer No. 20529



BOX PATENT

Attorney Docket No. 23758

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:) Group Art Unit: 1614
)
Gregory S. HAMILTON)
)
Serial No. 09/741,437)
)
Filed: December 21, 2000)

For: **HYDANTOIN DERIVATIVE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS,
AND METHODS OF USING SAME**

TRANSMITTAL LETTER

Commissioner for Patents
Washington, D.C. 20231

Sir:

Submitted herewith for filing in the U.S. Patent and
Trademark Office is the following:

- (1) Transmittal Letter;
- (2) Second Supplemental Information Disclosure Statement;
- (3) PTO-Form 1449;
- (4) Letter to the Examiner; and
- (5) Copies of (123) references cited.

Please charge any required fee, or credit any overpayment,
in connection with this matter to deposit Account No. 14-0112.

Respectfully submitted,

NATH & ASSOCIATES PLLC

Date: July 5, 2001
NATH & ASSOCIATES PLLC
1030 Fifteenth Street, N.W.
Sixth Floor
Washington, D.C. 20005
Tel: (202) 775-8383
FAX: (202) 775-8396
GMN:TLJ:JBG:\2sids.tl.wpd

Todd L. Juneau
Gary M. Nath
Reg. No. 26,965
Todd L. Juneau
Reg. No. 40,669
Customer No. 20529



BOX PATENT

Attorney Docket No. 23758

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:) Group Art Unit: 1614
)
Gregory S. HAMILTON)
)
Serial No. 09/741,437)
)
Filed: December 21, 2000)

For: **HYDANTOIN DERIVATIVE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS,
AND METHODS OF USING SAME**

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

Pursuant to Applicant's duty of disclosure under 37 C.F.R. §§1.56 and 1.97-1.99, the documents listed on the attached Form PTO-1449 are being brought to the attention of the Examiner in charge of the above-identified application. No fee is required for this submission because it is submitted prior to the mailing of a First Office Action on the merits.

Copies of the documents are attached herewith with a completed Form PTO-1449. The Examiner is respectfully requested to cite the documents listed on the attached Form PTO-1449 in the next Office Action. In so doing, the Examiner is respectfully requested to initial in the space adjacent to the listing of each document on the Form PTO-1449, and return a copy of the initialed Form PTO-1449 with the next communication to Applicants, to confirm that these documents have been considered by the Examiner

and made of record in this application.

If the Examiner has any questions or wishes to discuss this application, kindly telephone the undersigned at the below-listed number.

Respectfully submitted,

NATH & ASSOCIATES PLLC

Date: July 5, 2001

NATH & ASSOCIATES PLLC

1030 Fifteenth Street, N.W.

Sixth Floor

Washington, D.C. 20005

Tel: (202) 775-8383

FAX: (202) 775-8396

GMN:TLJ:JBG:\2sIDS.wpd

Todd L. Juneau
Gary M. Nath

Reg. No. 26,965

Todd L. Juneau

Reg. No. 40,669

Customer No. 20529



BOX PATENT
Attorney Docket No. 23758

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

In re Application of:)
Gregory S. HAMILTON)
Serial No. 09/741,437)
Filed: December 21, 2000)

Group Art Unit: 1614

JUL 10 2001

TECH CENTER 1600/2900

For: **HYDANTOIN DERIVATIVE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS,
AND METHODS OF USING SAME**

TRANSMITTAL LETTER

Commissioner for Patents
Washington, D.C. 20231

Sir:

Submitted herewith for filing in the U.S. Patent and
Trademark Office is the following:

- (1) Transmittal Letter;
- (2) Information Disclosure Statement;
- (3) PTO-Form 1449; and
- (4) Copies of Two-Hundred Fifty (250) references cited.

Please charge any required fee, or credit any overpayment,
in connection with this matter to deposit Account No. 14-0112.

Respectfully submitted,

NATH & ASSOCIATES PLLC

Date: July 5, 2001
NATH & ASSOCIATES PLLC
1030 Fifteenth Street, N.W.
Sixth Floor
Washington, D.C. 20005
Tel: (202) 775-8383
FAX: (202) 775-8396
GMN:TLJ:JBG:\ids.tl.wpd

Todd L. Juneau
Gary M. Nath
Reg. No. 26,965
Todd L. Juneau
Reg. No. 40,669
Customer No. 20529



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#2
M.J.
7/17/01

In re Application of:

Gregory S. HAMILTON

Serial No: 09/741,437

Group: 1614

Filed: December 21, 2000

For: **HYDANTOIN DERIVATIVE COMPOUNDS, PHARMACEUTICAL
COMPOSITIONS, AND METHODS OF USING SAME**

LETTER TO THE EXAMINER
REGARDING SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

Applicants herein provide a brief description of material described in each reference cited in the Second Supplemental Information Disclosure Statement, enclosed herewith. This outline is provided for the convenience of the Examiner and to advance the prosecution of the present application before the United States Patent and Trademark Office.

The Examiner's attention is drawn to the following IDS references containing biological information that the Examiner may find relevant for reviewing the subject matter of the present invention. The identification letters shown below (**AD**, **AE**, etc.) refer to the reference line numbers cited in the Second Supplemental Information Disclosure Statements.

Nerves- growth of; regeneration; degeneration:

AA, AB, AC, AD, AE, AF, AG, AH, AI, AJ, AK, AL, AS, AT,
BA, BB, BC, BD, BE, BF, BG, BH, BI, BJ, BL, BM, BN, BO,
BP, BR, BS, BT, CC, CD, CE, CH, CI, CL, CM, CN, CO, CP,
CR, CS, CT, DC, DF, DH, DI, DJ, DL, DM, DR, DS, DT, EA,
EC, EN, EP, ER, ES, ET, FL, FM, FN, FR, FS, FT, GM, GN,
GO, GP, GR, GS, GT, HL, HM, HN, HO, and HS.

Alzheimer's disease:

AA, AB, AC, AD, AE, AF, AG, AH, AI, AJ, AK, AL, AN, AP,
BA, BB, BC, BD, BE, BF, BG, BH, BI, BJ, BM, BN, BO, BP,
CB, CC, CD, CE, CI, CL, CM, CN, CO, CP, CT, DB, DC, DD,
DF, DH, DI, DJ, DL, DM, DR, EC, ED, EN, EP, FL, FM, GM,
GN, GO, GP, GR, GT, HL, HM, HN, HO, HP, and IL.

Parkinson's disease:

AA, AB, AC, AD, AE, AF, AG, AH, AI, AJ, AK, AL, AP, BA,
BB, BC, BD, BE, BF, BG, BH, BI, BJ, BM, BN, BO, BP, CC,
CD, CE, CI, CL, CM, CN, CO, CP, CT, DC, DF, DI, DL, DM,
DR, ED, EP, FM, FT, GM, GN, GO, GP, HL, HM, HN, and HO.

Amyotropic lateral sclerosis:

AA, AB, AC, AD, AE, AF, AG, AH, AJ, AK, BA, BB, BC, BD,
BE, BF, BG, BH, BI, BJ, BM, BN, BO, BP, CA, CC, CD, CE,
CI, CJ, CL, CM, CN, CO, CP, DA, DB, DG, DI, DK, DM, DP,
EL, EM, EO, EP, FL, GM, GN, GO, HO, and IL.

Cerebral ischemia:

AL, AS, BJ, BO, CC, CD, CE, CF, CL, CM, CO, DD, DO, EB,
EN, ES, FM, GM, GN, GO, HM, HN, and HP.

Degenerative disorders of nervous system; CNS disorders:

AA, AB, AC, AD, AE, AF, AG, AH, AI, AJ, AK, AM, BA, BB,
BC, BD, BE, BF, BG, BH, BI, BK, BM, BN, BS, CI, CK, CN,
CP, CT, DC, DD, DF, DH, DJ, ED, EN, EP, ET, FM, FO, FP,
FS, FT, GL, GN, GR, GS, and HM.

Memory or Dementia:

AN, AR, BM, CB, DA, DD, DE, DH, DJ, EC, ED, FM, GL, GO,
GP, HL, HO, and HR.

Eye or vision, or similar disorders:

AA, AE, AJ, CA, CE, CG, CJ, DA, DB, DC, DG, DK, DO, DP,
EA, EB, EL, EM, EO, FL, GN, GO, HP, HS, and IL.

Hair Growth or Alopecia:

BL, BO, CF, CG, CS, DN, FL, and IL.

Applicants have taken great care to ensure that the claims of the present invention are patentable over all cited references, but welcome and appreciate the Examiner's consideration of the same.

Please contact the undersigned attorney by telephone should
there be any questions or comments.

Respectfully submitted,

NATH & ASSOCIATES PLLC

Date: July 5, 2001

Todd L. Juneau
Gary M. Nath
Reg. No. 26,965
Todd L. Juneau
Reg. No. 40,669
Customer No. 20529

NATH & ASSOCIATES PLLC

1030 Fifteenth Street, N.W.
Sixth Floor
Washington, D.C. 20005-1503
(202) 775-8383
GMN:TLJ:JBG:\roadmap.wpd